

Yung-Jue Bang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/478695/yung-jue-bang-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

585
papers

40,834
citations

79
h-index

190
g-index

616
ext. papers

48,574
ext. citations

5.4
avg, IF

7.01
L-index

#	Paper	IF	Citations
585	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2102-2112	2.2	0
584	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102010	2.2	4
583	498 Evorpaccept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01 2021 , 9, A530-A530		0
582	Evorpaccept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology, The</i> , 2021 , 22, 1740-1751	21.7	2
581	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2021 , 53, 1096-1103	5.2	2
580	Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16078-e16078	2.2	
579	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021 , 7, 895-902	13.4	43
578	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , 2021 , 17, 491-501	3.6	43
577	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021 , 39, 966-977	2.2	42
576	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 1267-1277	12.9	10
575	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. <i>Clinical Cancer Research</i> , 2021 , 27, 2168-2178	12.9	22
574	A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors. <i>Clinical and Translational Science</i> , 2021 , 14, 990-1001	4.9	
573	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10 . <i>Clinical Cancer Research</i> , 2021 , 27, 1923-1931	12.9	23
572	Safety and Antitumor Activity of μ -PD-L1 Antibody as Monotherapy or in Combination with μ -TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 6393-6404	12.9	7
571	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021 , 24, 1330-1340	7.6	1
570	KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2021 , 17, 2847-2855	3.6	4
569	Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 5771-5780	12.9	1

568	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2021 , 1	7.6	8
567	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2419-2430	59.2	253
566	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2418-2426	2.2	33
565	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. <i>Lancet Oncology</i> , 2020 , 21, 1066-1076	21.7	60
564	TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy. <i>Cancers</i> , 2020 , 12,	6.6	3
563	Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study. <i>Targeted Oncology</i> , 2020 , 15, 75-84	5	5
562	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 846-854	12.9	43
561	Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts. <i>Cancer Science</i> , 2020 , 111, 536-547	6.9	24
560	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. <i>Cancer Science</i> , 2020 , 111, 513-527	6.9	14
559	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4513-4513	2.2	4
558	Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJ).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 278-278	2.2	32
557	Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1-positive (CPS ≥ 10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 427-427	2.2	10
556	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 430-430	2.2	8
555	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS463-TPS463	2.2	3
554	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 712-712	2.2	0
553	Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2020 , 52, 149-166	5.2	18
552	Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2020 , 52, 945-956	5.2	7
551	Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020 , 52, 1178-1187	5.2	6

550	Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS458-TPS458	2.2	2
549	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4540-4540	2.2	0
548	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1-10	2.2	786
547	The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy. <i>Cancer Medicine</i> , 2020 , 9, 43-51	4.8	10
546	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 1045-1056	21.7	16
545	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1571-1580	13.4	196
544	KRAS Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020 , 383, 1207-1217	59.2	469
543	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology</i> , 2020 , 21, 1353-1365	21.7	500
542	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). <i>European Journal of Cancer</i> , 2020 , 137, 272-284	7.5	32
541	Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 33-39	8.9	9
540	HER2-targeted therapies - a role beyond breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 33-48	19.4	225
539	Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3202-3210	12.9	10
538	A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2019 , 24, 1037-e636	5.7	3
537	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019 , 22, 828-837	7.6	112
536	Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer. <i>Oncology Letters</i> , 2019 , 17, 4383-4392	2.6	5
535	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 1206-1214	7.6	17
534	T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. <i>Journal of Clinical Oncology</i> , 2019 , 37, 318-327	2.2	346
533	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 3220-3228	12.9	99

532	Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. <i>Scientific Reports</i> , 2019 , 9, 11131	4.9	15
531	Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. <i>British Journal of Cancer</i> , 2019 , 121, 332-339	8.7	11
530	Adjuvant Treatment for Gastric Cancer 2019 , 353-357		
529	Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, LBA4007-LBA4007	2.2	102
528	An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 140-140	2.2	25
527	Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 65-65	2.2	13
526	A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS173-TPS173	2.2	2
525	A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS180-TPS180	2.2	3
524	Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea. <i>Chinese Clinical Oncology</i> , 2019 , 8, 27	2.3	1
523	Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells. <i>Cancer Research and Treatment</i> , 2019 , 51, 451-463	5.2	9
522	Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology. <i>Cancer Research and Treatment</i> , 2019 , 51, 832-840	5.2	6
521	Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 886-900	5.2	2
520	Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 1167-1179	5.2	14
519	The prognostic role of soluble transforming growth factor- β (sTGF β) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 257-257	2.2	
518	Predictive role of temporal changes in intratumoral metabolic heterogeneity during palliative chemotherapy in advanced pancreatic cancer patients: A prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 311-311	2.2	
517	GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 932-940	7.6	5
516	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. <i>Future Oncology</i> , 2019 , 15, 943-952	3.6	59
515	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. <i>Cancers</i> , 2019 , 11,	6.6	13

514	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , 2019 , 4, e000575	6	5
513	A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. <i>European Journal of Cancer</i> , 2019 , 108, 17-24	7.5	17
512	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. <i>Future Oncology</i> , 2019 , 15, 567-577	3.6	18
511	Use of olaparib in patients with advanced gastric cancer - Authors' reply. <i>Lancet Oncology</i> , 2018 , 19, e76	21.7	2
510	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. <i>Cancer Science</i> , 2018 , 109, 771-776	6.9	29
509	Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2018 , 23, 155-e17	5.7	14
508	Long-term trastuzumab (Herceptin [®]) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. <i>BMC Cancer</i> , 2018 , 18, 295	4.8	15
507	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. <i>JAMA Oncology</i> , 2018 , 4, e180013	13.4	834
506	Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. <i>Annals of Oncology</i> , 2018 , 29, 2052-2060	10.3	241
505	Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. <i>Cancer Letters</i> , 2018 , 430, 123-132	9.9	28
504	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. <i>Cancer Treatment Reviews</i> , 2018 , 66, 104-113	14.4	57
503	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , 2018 , 392, 123-133	40	624
502	A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2586-2586	2.2	6
501	Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3014-3014	2.2	22
500	The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4010-4010	2.2	13
499	Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4021-4021	2.2	1
498	Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4031-4031	2.2	9
497	Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4062-4062	2.2	7

496	Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4079-4079	2.2	1
495	A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4133-TPS4133	2.2	3
494	KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4136-TPS4136	2.2	3
493	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- β in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 100-100	2.2	6
492	The role of soluble TGF-beta and its dynamics for predicting the prognosis in unresectable pancreatic cancer patients treated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 288-288	2.2	1
491	A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 560-560	2.2	27
490	Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 92-92	2.2	15
489	JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS195-TPS195	2.2	12
488	Prognostic implication of soluble programmed death-ligand 1 (sPDL1) and its dynamic changes during FOLFIRINOX chemotherapy in unresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 306-306	2.2	
487	TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study. <i>Cancer Research and Treatment</i> , 2018 , 50, 398-404	5.2	2
486	A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS3114-TPS3114	2.2	
485	S-1-Induced Lacrimal Drainage Obstruction and Its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-institutional Study. <i>Cancer Research and Treatment</i> , 2018 , 50, 30-39	5.2	8
484	Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2018 , 50, 835-842	5.2	41
483	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 164-174	7.6	12
482	Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 254-262	7.6	40
481	Phosphorylated Akt Expression as a Favorable Prognostic Factor for Patients Undergoing Curative Resection and Adjuvant Chemoradiotherapy for Proximal Extrahepatic Bile Duct Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 158-162	2.7	
480	AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 566-577	6.1	74
479	Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy. <i>Targeted Oncology</i> , 2017 , 12, 211-218	5	12

478	Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1145-1154	6.1	33
477	Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1255-1261	8.9	4
476	A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2017 , 12, 463-474	5	50
475	Risk stratification and prognostic nomogram for post-recurrence overall survival in patients with recurrent extrahepatic cholangiocarcinoma. <i>Hpb</i> , 2017 , 19, 421-428	3.8	7
474	Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 620-627	13.4	165
473	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1637-1651	21.7	174
472	Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. <i>Cancer Letters</i> , 2017 , 411, 162-170	9.9	10
471	Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. <i>Oncotarget</i> , 2017 , 8, 2329-2341	3.3	39
470	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017 , 12, e0172307	3.7	8
469	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. <i>BMC Cancer</i> , 2017 , 17, 646	4.8	12
468	Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , 2017 , 49, 1033-1043	5.2	10
467	CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy. <i>Cancer Research and Treatment</i> , 2017 , 49, 807-815	5.2	6
466	HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2558-2567	2.2	73
465	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2535-2541	22.4	244
464	Findings of a 1303 Korean whole-exome sequencing study. <i>Experimental and Molecular Medicine</i> , 2017 , 49, e356	12.8	23
463	Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2017 , 22, 1069-1075	4.2	5
462	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017 , 23, 5981-5992	12.9	73
461	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5671-5678	12.9	91

460	Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 767-773	13.4	52
459	HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 228-238	6.1	25
458	Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. <i>International Journal of Cancer</i> , 2017 , 140, 109-119	7.5	35
457	Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 899-904	8.9	13
456	KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. <i>Annals of Oncology</i> , 2017 , 28, iii153	10.3	7
455	Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with -amplified gastric cancer. <i>Oncotarget</i> , 2017 , 8, 79546-79555 ¹⁶	2.2	102
454	KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4003-4003	2.2	102
453	KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4012-4012	2.2	39
452	Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4067-4067	2.2	8
451	Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4136-TPS4136	2.2	8
450	Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution. <i>Oncotarget</i> , 2017 , 8, 78076-78085	3.3	2
449	Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. <i>Oncotarget</i> , 2017 , 8, 79441-79452	3.3	18
448	Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea. <i>Cancer Research and Treatment</i> , 2017 , 49, 578-587	5.2	16
447	Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution. <i>Cancer Research and Treatment</i> , 2017 , 49, 473-483	5.2	17
446	Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis. <i>Cancer Research and Treatment</i> , 2017 , 49, 643-655	5.2	12
445	Antibodies that Inhibit Specific Cellular Pathways in Gastric Cancer 2017 , 101-113		1
444	Prospective evaluation of the clinical implications of the tumor metabolism and chemotherapy-related changes in advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 261-261	2.2	1
443	Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 416-416	2.2	

442	Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 460-460	2.2	
441	Dynamics of soluble programmed death-ligand 1 (soluble PDL1) during chemotherapy and its prognostic implication in cancer patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11542-11542	2.2	
440	Dose-exposure-response relationship between AZD6738 and peripheral monocytes.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14063-e14063	2.2	1
439	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. <i>Gastric Cancer</i> , 2016 , 19, 421-430	7.6	10
438	Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 597-606	7.6	21
437	Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. <i>Nutrition and Cancer</i> , 2016 , 68, 750-5	2.8	
436	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2728-35	2.2	138
435	Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016 , 115, 164-71	8.7	30
434	Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. <i>Lancet Oncology</i> , 2016 , 17, 309-318	21.7	374
433	Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. <i>Gastric Cancer</i> , 2016 , 19, 1066-1079	7.6	29
432	Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System?. <i>Annals of Surgical Oncology</i> , 2016 , 23, 1234-43	3.1	12
431	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 1095-1103	7.6	26
430	Pertuzumab in gastrointestinal cancer. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 243-53	5.4	9
429	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 418-51	2.2	361
428	Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+ gastric cancer and advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2502-2502	2.2	4
427	Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3502-3502	2.2	90
426	A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4011-4011	2.2	27
425	Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4037-4037	2.2	10

424	Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4041-4041	2.2	3
423	Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4043-4043	2.2	10
422	Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5581-5581	2.2	21
421	Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9067-9067	2.2	31
420	ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E-mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS2604-TPS2604	2.2	4
419	Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC + chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4135-TPS4135	2.2	5
418	Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4137-TPS4137	2.2	4
417	KEYNOTE-062: Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4138-TPS4138	2.2	1
416	The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4144-TPS4144	2.2	3
415	Pembrolizumab (MK-3475) plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer: Preliminary safety data from KEYNOTE-059.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 161-161	2.2	5
414	Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 309-309	2.2	5
413	Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) - a study by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4133-TPS4133	2.2	3
412	Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS183-TPS183	2.2	10
411	Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS184-TPS184	2.2	3
410	KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS185-TPS185	2.2	20
409	More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. <i>PLoS ONE</i> , 2016 , 11, e0145692	3.7	12
408	Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. <i>PLoS ONE</i> , 2016 , 11, e0151406	3.7	13
407	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016 , 7, 76604-76612	3.3	77

406	Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2016 , 48, 28-36	5.2	18
405	The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. <i>Cancer Research and Treatment</i> , 2016 , 48, 171-9	5.2	46
404	VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma. <i>Cancer Research and Treatment</i> , 2016 , 48, 518-26	5.2	20
403	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016 , 48, 1045-55	5.2	7
402	Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. <i>Cancer Research and Treatment</i> , 2016 , 48, 990-7	5.2	11
401	Effect of combined consideration of distinct signatures of VEGF and soluble VEGFR2 on prognostic implication in gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 56-56	2.2	
400	Prediction of metastatic pancreatic cancer patients survival using both host immunity and tumor metabolic activity.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 411-411	2.2	
399	Association of reduction of tumor metabolism with prognosis of advanced gastric cancer patients treated with palliative chemotherapy: Prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 31-31	2.2	
398	Role of adjuvant chemoradiotherapy for duodenal cancer: An update of the experience at a single institution.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 370-370	2.2	
397	A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2521-2521	2.2	1
396	Korean Cancer Patients Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10067-10067	2.2	
395	Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy. <i>Anticancer Research</i> , 2016 , 36, 5455-5461	2.3	
394	Therapeutic implication of HER2 in advanced biliary tract cancer. <i>Oncotarget</i> , 2016 , 7, 58007-58021	3.3	46
393	Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy. <i>Journal of Breast Cancer</i> , 2016 , 19, 394-401	3	3
392	Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 346-9	2.7	2
391	Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. <i>Targeted Oncology</i> , 2016 , 11, 815-824	5.2	33
390	Src as a Therapeutic Target in Biliary Tract Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1515-24	6.1	8
389	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , 2016 , 17, 717-726	21.7	716

388	A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors. <i>Cancer Medicine</i> , 2016 , 5, 1454-63	4.8	9
387	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2520-9	12.9	47
386	High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2015 , 117, 165-70	5.3	36
385	A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 1175-82	3.5	1
384	The Prognostic Importance of the Number of Metastatic Lymph Nodes for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiotherapy for Extrahepatic Bile Duct Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2015 , 19, 1833-41	3.3	5
383	Capecitabine for the treatment of gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 1471-81	4.2	8
382	Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer. <i>Oncologist</i> , 2015 , 20, 896-7	5.7	14
381	Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3858-65	2.2	202
380	KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. <i>Annals of Surgical Oncology</i> , 2015 , 22, 187-94	3.1	41
379	Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. <i>Clinical Epigenetics</i> , 2015 , 7, 63	7.7	15
378	Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. <i>BMC Cancer</i> , 2015 , 15, 690	4.8	7
377	Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. <i>BMC Cancer</i> , 2015 , 15, 721	4.8	17
376	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2015 , 17, 33	8.3	110
375	Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. <i>Cancer</i> , 2015 , 121, 2612-7	6.4	44
374	Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 253-66	3.8	9
373	Effect of lapatinib on oral digoxin absorption in patients. <i>Clinical Pharmacology in Drug Development</i> , 2015 , 4, 449-53	2.3	8
372	Treatment for unresectable gastric cancer. <i>Journal of the Korean Medical Association</i> , 2015 , 58, 209	0.5	1
371	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. <i>PLoS ONE</i> , 2015 , 10, e0139749	3.7	142

370	HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2015 , 18, 476-84	7.6	262
369	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. <i>Oncologist</i> , 2015 , 20, 926-33	5.7	7
368	Abstract CT328: Exploratory genetic analysis of tumors from a phase I/II dose escalation study of GSK2636771 in patients (pts) with PTEN deficient advanced tumors 2015 ,		2
367	Randomized controlled trial of comparing gastrectomy (Gx) plus chemotherapy (CTX) with CTX alone in advanced gastric cancer (AGC) with a single non-curable factor: JCOG 0705/KGCA01 study (REGATTA).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 200-200	2.2	5
366	Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3026-3026	2.2	16
365	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG) Final overall and subgroup results.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4003-4003	2.2	8
364	METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4012-4012	2.2	65
363	A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4014-4014	2.2	30
362	Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4050-4050	2.2	1
361	Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 523-523	2.2	3
360	Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4135-TPS4135	2.2	2
359	Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3-3	2.2	45
358	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9-9	2.2	6
357	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. <i>American Journal of Cancer Research</i> , 2015 , 5, 3376-88	4.4	6
356	TGF- β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. <i>Cancer Research and Treatment</i> , 2015 , 47, 101-9	5.2	13
355	Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. <i>Cancer Research and Treatment</i> , 2015 , 47, 274-81	5.2	5
354	Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 687-96	5.2	9
353	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2015 , 47, 607-15	5.2	76

352	Adjuvant treatment patterns and clinical outcomes in patients with curative resected ampulla of Vater cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 415-415	2.2	
351	Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 133-133	2.2	
350	Change of skeletal muscle index during the chemotherapy as a prognostic factor of survival in pancreatic cancer patients receiving palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 363-363	2.2	
349	Weight loss at the first month of palliative chemotherapy to predict survival outcomes in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 83-83	2.2	
348	Measurement of soluble Programmed Death-Ligand 1 (soluble PD-L1) to predict survival in biliary tract cancer patients treated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11094-11094	2.2	
347	Quality of life in the trastuzumab for gastric cancer trial. <i>Oncologist</i> , 2014 , 19, 712-9	5.7	33
346	Crizotinib in ROS1-rearranged non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1963-71	59.2	1267
345	Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1389-96	21.7	578
344	Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 447-55	3.5	3
343	Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1567-74	4.9	11
342	Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2039-49	2.2	407
341	The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. <i>Journal of Pain and Symptom Management</i> , 2014 , 48, 13-25	4.8	15
340	Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. <i>Journal of Korean Medical Science</i> , 2014 , 29, 1094-101	4.7	14
339	Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker. <i>International Journal of Cancer</i> , 2014 , 134, 72-80	7.5	34
338	Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10, 38-52	1.9	14
337	Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10, 237-45	1.9	34
336	A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. <i>BMC Cancer</i> , 2014 , 14, 795	4.8	22
335	Abstract CT215: A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cancer 2014 ,		9

334	A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2514-2514	2.2	17
333	A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2517-2517	2.2	9
332	Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2520-2520	2.2	27
331	Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2535-2535	2.2	27
330	JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, T9911-17-T9911-17	2.2	2
329	Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, T9911-19-T9911-19	2.2	5
328	Comparison of concurrent chemoradiotherapy and chemotherapy alone for locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 351-351	2.2	1
327	A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer. <i>Cancer Research and Treatment</i> , 2014 , 46, 234-42	5.2	11
326	A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions. <i>Cancer Research and Treatment</i> , 2014 , 46, 280-7	5.2	1
325	Biomarkers to predict sensitivity to HER2-targeting treatment in HER2-positive advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4062-4062	2.2	
324	Metabolic landscape and prognostic value of HER2 in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4061-4061	2.2	
323	Real-world treatment patterns among patients with advanced gastric cancer in South Korea.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 152-152	2.2	
322	Metabolic landscape using 18F-FDG PET and its clinical significances in advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 252-252	2.2	
321	Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. <i>Anticancer Research</i> , 2014 , 34, 4275-80	2.3	6
320	Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery. <i>Anticancer Research</i> , 2014 , 34, 6685-90	2.3	2
319	Adjuvant and neoadjuvant therapy for gastric cancer. <i>Current Treatment Options in Oncology</i> , 2013 , 14, 311-20	5.4	14
318	Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy. <i>Breast Cancer</i> , 2013 , 20, 167-73	3.4	14
317	Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1435-43	3.5	12

316	Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 843-51	3.5	33
315	Free-breathing dynamic contrast-enhanced MRI of the abdomen and chest using a radial gradient echo sequence with K-space weighted image contrast (KWIC). <i>European Radiology</i> , 2013 , 23, 1352-60	8	45
314	Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3935-43	2.2	358
313	Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1667-70	9.7	58
312	Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013 , 49, 1565-77	7.5	119
311	Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. <i>International Journal of Cancer</i> , 2013 , 132, 2209-16	7.5	44
310	Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. <i>Investigational New Drugs</i> , 2013 , 31, 1547-58	4.3	14
309	Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. <i>Gastric Cancer</i> , 2013 , 16, 581-9	7.6	25
308	OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. <i>Cancer Letters</i> , 2013 , 335, 145-52	9.9	85
307	Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1600-7	9.7	102
306	Nomogram prediction of survival and recurrence in patients with extrahepatic bile duct cancer undergoing curative resection followed by adjuvant chemoradiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 87, 499-504	4	6
305	Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 947-56; quiz 957	2.4	28
304	Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1445-50	8.9	57
303	Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients. <i>Pathobiology</i> , 2013 , 80, 127-37	3.6	42
302	Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 16-26	6.1	47
301	RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 865-77	6.1	91
300	CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 16868-73	11.5	45
299	Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. <i>Journal of Surgical Oncology</i> , 2013 , 107, 511-6	2.8	35

298	Registry of gastric cancer treatment evaluation (REGATE): II treatment practice. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013 , 9, 373-80	1.9	7
297	Establishment and characterization of seven human breast cancer cell lines including two triple-negative cell lines. <i>International Journal of Oncology</i> , 2013 , 43, 2073-81	4.4	5
296	The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer. <i>BMC Cancer</i> , 2013 , 13, 576	4.8	11
295	Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. <i>PLoS ONE</i> , 2013 , 8, e64271	3.7	61
294	Phase I study (A8471004) in Asian patients of PF-03446962, a fully human mab against ALK-1 receptor involved in tumor angiogenesis: Safety, pharmacokinetics (PK), and pharmacodynamics (PD).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11031-11031	2.2	1
293	Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2565-2565	2.2	1
292	Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAB), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3004-3004	2.2	3
291	Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4013-4013	2.2	23
290	Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8032-8032	2.2	26
289	MetGastric: A randomized phase III study of onartuzumab (MetMab) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS4155-TPS4155	2.2	12
288	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC) A study by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS4157-TPS4157	2.2	2
287	Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA4001-LBA4001	2.2	64
286	A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11-11	2.2	17
285	The influence of treatment response on the impact of resection margin status after preoperative chemoradiotherapy in rectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 505-505	2.2	8
284	CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. <i>World Journal of Gastroenterology</i> , 2013 , 19, 1438-43	5.6	11
283	Clinical Implications of VEGF, TGF- β , and IL-1 β in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013 , 45, 325-33	5.2	34
282	Phosphorylated Akt expression as a favorable prognostic factor for patients undergoing curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 182-182	2.2	
281	The impact of diabetes mellitus and metformin on survival of patients with advanced pancreatic cancer receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4044-4044	2.2	1

280	Application of mechanism-based PKPD model to identify optimal dosing regimens for future development of oraxol.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e13505-e13505	2.2	
279	The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15066-e15066	2.2	
278	Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA4001-LBA4001	2.2	
277	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 303-13	4.8	52
276	Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2012 , 20, 395-403	3.9	16
275	NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. <i>International Journal of Oncology</i> , 2012 , 40, 1259-66	4.4	38
274	Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. <i>Lancet, The</i> , 2012 , 379, 315-21	4.0	1085
273	Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers. <i>Laboratory Investigation</i> , 2012 , 92, 1033-44	5.9	31
272	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology, The</i> , 2012 , 13, 1011-9	21.7	983
271	The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. <i>Investigational New Drugs</i> , 2012 , 30, 2148-60	4.3	14
270	Distant metastasis risk stratification for patients undergoing curative resection followed by adjuvant chemoradiation for extrahepatic bile duct cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, 81-7	4	6
269	Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. <i>Acta Oncologica</i> , 2012 , 51, 528-36	3.2	24
268	Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. <i>Cancer Letters</i> , 2012 , 316, 77-84	9.9	6
267	Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. <i>Cancer Letters</i> , 2012 , 321, 128-36	9.9	10
266	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. <i>European Journal of Cancer</i> , 2012 , 48, 2941-53	7.5	104
265	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. <i>Lung Cancer</i> , 2012 , 77, 460-3	5.9	71
264	Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 381-9	3.5	16
263	Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. <i>PLoS ONE</i> , 2012 , 7, e39943	3.7	18

262	Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients. <i>International Journal of Nanomedicine</i> , 2012 , 7, 5555-64	7.3	6
261	Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data. <i>Journal of Breast Cancer</i> , 2012 , 15, 427-33	3	10
260	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. <i>Cancer</i> , 2012 , 118, 3579-86	6.4	41
259	Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. <i>Cancer</i> , 2012 , 118, 6162-70	6.4	64
258	A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. <i>Investigational New Drugs</i> , 2012 , 30, 1164-74	4.3	19
257	Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer. <i>Investigational New Drugs</i> , 2012 , 30, 1404-12	4.3	14
256	Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2012 , 14, 391-5	3.6	13
255	Treatment of ALK-positive non-small cell lung cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2012 , 136, 1201-4	5	26
254	Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012 , 35, 549-56	2.7	21
253	The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. <i>Japanese Journal of Clinical Oncology</i> , 2012 , 42, 1020-7	2.8	6
252	Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012 , 35, 136-40	2.7	28
251	Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, e147-50	2.2	43
250	Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 180-94	2.9	30
249	ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. <i>Oncology</i> , 2012 , 83, 218-27	3.6	18
248	Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. <i>Oncology</i> , 2012 , 83, 57-66	3.6	19
247	Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 439-51	6.1	60
246	Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012 , 35, 533-6	2.7	16
245	Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. <i>Anti-Cancer Drugs</i> , 2012 , 23, 288-97	2.4	14

244	Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 637-48	3	62
243	Abstract 4017: Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers 2012 ,		3
242	Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4118-4118	2.2	10
241	Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4124-4124	2.2	8
240	Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7508-7508	2.2	46
239	Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5-5	2.2	10
238	A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 54-54	2.2	7
237	Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA3-LBA3	2.2	28
236	Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. <i>PLoS ONE</i> , 2012 , 7, e33322	3.7	37
235	Postoperative chemoradiotherapy in high risk locally advanced gastric cancer. <i>Radiation Oncology Journal</i> , 2012 , 30, 213-7	2.5	7
234	Adjuvant chemotherapy: an option for Asian patients only?. <i>Recent Results in Cancer Research</i> , 2012 , 196, 291-305	1.5	2
233	Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3624-3624	2.2	
232	A phase I/II study of oral paclitaxel in patients (pts) with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14572-e14572	2.2	
231	Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4081-4081	2.2	
230	The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. <i>Anticancer Research</i> , 2012 , 32, 1547-53	2.3	24
229	Self-Rated Pain Assessment by Patients With HER2-Positive Advanced Gastric/GEJ Cancer Treated With 5-FU/Capecitabine and Cisplatin With or Without Trastuzumab: Exploratory QOL Analysis From the Phase III ToGA Study. <i>Gastroenterology</i> , 2011 , 140, S-204	13.3	2
228	Epigenetic-based therapies in cancer: progress to date. <i>Drugs</i> , 2011 , 71, 2391-403	12.1	81
227	Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection. <i>BMC Cancer</i> , 2011 , 11, 188	4.8	7

226	The potential for crizotinib in non-small cell lung cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2011 , 3, 279-91	5.4	62
225	Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. <i>Cancer Letters</i> , 2011 , 302, 155-65	9.9	39
224	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology, The</i> , 2011 , 12, 1004-12	21.7	732
223	Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. <i>New England Journal of Medicine</i> , 2011 , 364, 501-13	59.2	1817
222	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. <i>Breast Cancer Research</i> , 2011 , 13, R22	8.3	158
221	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1474-80	8.9	131
220	Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 905-12	8.9	53
219	Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. <i>Cancer Science</i> , 2011 , 102, 1388-95	6.9	41
218	Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. <i>Histopathology</i> , 2011 , 59, 822-31	7.3	112
217	Age . <i>Breast Journal</i> , 2011 , 17, 75-8	1.2	9
216	Phase II study of sunitinib as second-line treatment for advanced gastric cancer. <i>Investigational New Drugs</i> , 2011 , 29, 1449-58	4.3	157
215	High serum TGF- β predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 107-14	4.4	16
214	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 1301-8	4.9	24
213	Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1323-31	3.5	28
212	Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 165-75	3.5	7
211	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (IFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1017-26	3.5	4
210	Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1045-55	3.5	59
209	Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes. <i>Cellular Oncology (Dordrecht)</i> , 2011 , 34, 45-54	7.2	7

208	Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer. <i>BMC Gastroenterology</i> , 2011 , 11, 56	3	45
207	Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2011 , 11, 452	4.8	52
206	RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2011 , 12, 9-46	4.6	72
205	Capecitabine in gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1791-806	3.5	9
204	VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. <i>Diagnostic Molecular Pathology</i> , 2011 , 20, 143-7		3
203	Clinicopathologic characteristics of patients with stage III/IV (M0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. <i>Diagnostic Molecular Pathology</i> , 2011 , 20, 94-100		24
202	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 942-6	8.9	354
201	Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. <i>Oncology</i> , 2011 , 80, 395-405	3.6	45
200	Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center. <i>Hematology</i> , 2011 , 16, 73-9	2.2	5
199	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4803-10	2.2	364
198	Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 593-9	2.8	51
197	Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 245-52	2.8	5
196	Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. <i>Tumori</i> , 2011 , 97, 280-5	1.7	3
195	Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 125-9	2.7	9
194	Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. <i>Cancer Science</i> , 2010 , 101, 793-9	6.9	23
193	Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: a retrospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 1537-42	4	22
192	Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy. <i>Journal of Korean Medical Science</i> , 2010 , 25, 235-9	4.7	8
191	The Sequencing of Chemotherapy and Radiotherapy in Breast Cancer Patients after Mastectomy. <i>Tumori</i> , 2010 , 96, 28-33	1.7	3

190	Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer. <i>Journal of Korean Medical Science</i> , 2010 , 25, 684-90	4.7	8
189	Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity. <i>Japanese Journal of Clinical Oncology</i> , 2010 , 40, 112-8	2.8	35
188	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1693-703	59.2	3577
187	Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, G126-32	5.1	23
186	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 68, 427-32	5.9	5
185	P-cadherin expression in gastric carcinoma: its regulation mechanism and prognostic significance. <i>Human Pathology</i> , 2010 , 41, 877-85	3.7	12
184	RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. <i>Cancer Letters</i> , 2010 , 299, 22-8	9.9	39
183	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. <i>Lancet, The</i> , 2010 , 376, 687-97	40	4587
182	Trastuzumab for gastric cancer treatment [Authors' reply]. <i>Lancet, The</i> , 2010 , 376, 1735-1736	40	4
181	A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. <i>Anti-Cancer Drugs</i> , 2010 , 21, 777-84	2.4	16
180	Prognostic factors affecting the outcome of salvage radiotherapy for isolated locoregional recurrence after mastectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 23-7	2.7	13
179	Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 320-5	8.9	41
178	DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells. <i>International Journal of Oncology</i> , 2010 , 36, 1563-72	4.4	14
177	Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 2044-6	8.9	69
176	A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 527-36	3.5	32
175	Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells. <i>Molecules and Cells</i> , 2010 , 30, 107-12	3.5	55
174	Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. <i>BMC Cancer</i> , 2010 , 10, 448	4.8	34
173	Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. <i>BMC Cancer</i> , 2010 , 10, 557	4.8	40

172	Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. <i>Cancer</i> , 2010 , 116, 2890-901	6.4	40
171	KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. <i>Molecular Carcinogenesis</i> , 2010 , 49, 353-62	5	92
170	Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 1186-90	4	7
169	Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. <i>Journal of Korean Medical Science</i> , 2009 , 24, 910-7	4.7	17
168	Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. <i>PLoS ONE</i> , 2009 , 4, e5933	3.7	78
167	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2526-36	6.1	61
166	Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. <i>Oncologist</i> , 2009 , 14, 540-7	5.7	16
165	A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. <i>Oncology</i> , 2009 , 76, 326-32	3.6	23
164	Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. <i>Carcinogenesis</i> , 2009 , 30, 753-7	4.6	77
163	Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. <i>BMC Cancer</i> , 2009 , 9, 345	4.8	31
162	The role of PET/CT in detection of gastric cancer recurrence. <i>BMC Cancer</i> , 2009 , 9, 73	4.8	62
161	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 153-60	4.4	39
160	Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. <i>Abdominal Imaging</i> , 2009 , 34, 430-40		41
159	Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. <i>Annals of Hematology</i> , 2009 , 88, 829-38	3	14
158	Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 497-507	3.5	26
157	Results of breast-conserving therapy for multifocal or multicentric breast cancers. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009 , 5, 200-205	1.9	1
156	Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 800-5	4	32
155	Does adjuvant radiotherapy suppress liver regeneration after partial hepatectomy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 67-72	4	4

154	Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 436-41	4	50
153	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. <i>Lung Cancer</i> , 2009 , 65, 80-4	5.9	105
152	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2009 , 65, 204-7	5.9	24
151	Ramosectron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009 , 39, 111-5 ^{2.8}		5
150	Public awareness of gastric cancer risk factors and disease screening in a high risk region: a population-based study. <i>Cancer Research and Treatment</i> , 2009 , 41, 59-66	5.2	25
149	Effect of Suboptimal Chemotherapy on Preoperative Chemoradiation in Rectal Cancer. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2009 , 27, 78		1
148	Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. <i>Laboratory Investigation</i> , 2008 , 88, 153-60	5.9	31
147	Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2008 , 109, 359-63	4.9	16
146	Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. <i>BMC Cancer</i> , 2008 , 8, 148	4.8	56
145	The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. <i>BMC Cancer</i> , 2008 , 8, 307	4.8	92
144	Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. <i>BMC Cancer</i> , 2008 , 8, 374	4.8	41
143	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2008 , 60, 401-7	5.9	72
142	Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. <i>Lung Cancer</i> , 2008 , 61, 30-4	5.9	76
141	Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer. <i>Cancer Investigation</i> , 2008 , 26, 152-8	2.1	24
140	DNA methyltransferase 3B acts as a co-repressor of the human polycomb protein hPc2 to repress fibroblast growth factor receptor 3 transcription. <i>International Journal of Biochemistry and Cell Biology</i> , 2008 , 40, 2462-71	5.6	8
139	Overexpression of A-kinase anchoring protein 12A activates sterol regulatory element binding protein-2 and enhances cholesterol efflux in hepatic cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2008 , 40, 2534-43	5.6	5
138	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. <i>Cancer Letters</i> , 2008 , 272, 296-306	9.9	104
137	Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 368, 318-22	3.4	75

136	A-kinase anchoring protein 12 regulates the completion of cytokinesis. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 373, 85-9	3.4	11
135	Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 504-6	2.8	48
134	Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells. <i>Experimental and Molecular Medicine</i> , 2008 , 40, 639-46	12.8	13
133	Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration. <i>Journal of Biological Chemistry</i> , 2008 , 283, 32762-70	5.4	46
132	Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 607-15	6.1	49
131	Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 589-95	2.8	22
130	Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. <i>Cancer Research</i> , 2008 , 68, 1916-26	10.1	60
129	Aggressiveness of cancer-care near the end-of-life in Korea. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 381-6	2.8	85
128	Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin 2008 ,		4
127	Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 263-70	3.5	10
126	Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. <i>Journal of Molecular Medicine</i> , 2008 , 86, 117-28	5.5	40
125	DNA methyltransferase 3B mutant in ICF syndrome interacts non-covalently with SUMO-1. <i>Journal of Molecular Medicine</i> , 2008 , 86, 1269-77	5.5	10
124	DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. <i>Molecular Carcinogenesis</i> , 2008 , 47, 326-37	5	103
123	Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. <i>Cancer Research and Treatment</i> , 2008 , 40, 81-6	5.2	6
122	Results of Breast Conserving Surgery and Subsequent Postoperative Radiotherapy for Cases of Breast Cancer. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2008 , 26, 142		2
121	Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. <i>International Journal of Oncology</i> , 2008 , 32, 89-95	1	51
120	Negative Impact of Heat Exposure on Cosmesis after Conservative Treatment for Breast Cancer. <i>Tumori</i> , 2007 , 93, 591-596	1.7	4
119	Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer. <i>Journal of Korean Medical Science</i> , 2007 , 22 Suppl, S115-21	4.7	22

118	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. <i>BMC Cancer</i> , 2007 , 7, 203	4.8	111
117	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. <i>BMC Cancer</i> , 2007 , 7, 63	4.8	55
116	Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. <i>Journal of Molecular Medicine</i> , 2007 , 85, 1137-48	5.5	52
115	Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. <i>Supportive Care in Cancer</i> , 2007 , 15, 631-636	3.9	13
114	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. <i>Expert Review of Molecular Diagnostics</i> , 2007 , 7, 821-36	3.8	9
113	Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial. <i>Japanese Journal of Clinical Oncology</i> , 2007 , 37, 501-8	2.8	7
112	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 313-9	1.9	49
111	DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 355, 72-7	3.4	66
110	Zinc-fingers and homeoboxes 1 (ZHX1) binds DNA methyltransferase (DNMT) 3B to enhance DNMT3B-mediated transcriptional repression. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 355, 318-23	3.4	33
109	Histone deacetylase inhibitors for cancer therapy. <i>Epigenetics</i> , 2006 , 1, 14-23	5.7	51
108	High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. <i>Clinical Cancer Research</i> , 2006 , 12, 4232-6	12.9	34
107	Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. <i>Clinical Cancer Research</i> , 2006 , 12, 2538-44	12.9	215
106	Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. <i>Circulation</i> , 2006 , 113, 51-9	16.7	281
105	First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1274-82	1.9	51
104	Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006 , 36, 344-50	2.8	25
103	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2006 , 54, 201-7	5.9	31
102	Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 3085-95	6.1	87
101	Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome. <i>Journal of Korean Medical Science</i> , 2006 , 21, 633-8	4.7	5

100	CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience. <i>Supportive Care in Cancer</i> , 2006 , 14, 103-8	3.9	55
99	The synergism between Belotecan and cisplatin in gastric cancer. <i>Cancer Research and Treatment</i> , 2006 , 38, 159-67	5.2	6
98	Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. <i>Anticancer Research</i> , 2006 , 26, 3429-38	2.3	16
97	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2493-501	2.2	681
96	Adenovirus-uteroglobin suppresses COX-2 expression via inhibition of NF-kappaB activity in lung cancer cells. <i>Lung Cancer</i> , 2005 , 48, 201-9	5.9	11
95	Antitumor promotional effects of a novel intestinal bacterial metabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin. <i>Carcinogenesis</i> , 2005 , 26, 359-67	4.6	67
94	Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. <i>Oncology Reports</i> , 2005 , 14, 481	3.5	
93	Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. <i>Blood</i> , 2005 , 106, 3785-90	2.2	145
92	Cytotoxic effects of pemetrexed in gastric cancer cells. <i>Cancer Science</i> , 2005 , 96, 365-71	6.9	27
91	Oocyte-based screening of cytokinesis inhibitors and identification of pectenotoxin-2 that induces Bim/Bax-mediated apoptosis in p53-deficient tumors. <i>Oncogene</i> , 2005 , 24, 4813-9	9.2	55
90	TGF-beta1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27(Kip1) CDK inhibitor in hepatoma cells replated on fibronectin. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2005 , 1743, 151-61	4.9	28
89	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. <i>International Journal of Cancer</i> , 2005 , 113, 109-15	7.5	139
88	Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. <i>Journal of Korean Medical Science</i> , 2005 , 20, 806-10	4.7	16
87	The signaling network of transforming growth factor beta1, protein kinase Cdelta, and integrin underlies the spreading and invasiveness of gastric carcinoma cells. <i>Molecular and Cellular Biology</i> , 2005 , 25, 6921-36	4.8	39
86	Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005 , 35, 380-5	2.8	14
85	The endogenous ratio of Smad2 and Smad3 influences the cytostatic function of Smad3. <i>Molecular Biology of the Cell</i> , 2005 , 16, 4672-83	3.5	59
84	Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis. <i>Cancer Research</i> , 2005 , 65, 1952-60	10.1	85
83	Cell adhesion status-dependent histone acetylation is regulated through intracellular contractility-related signaling activities. <i>Journal of Biological Chemistry</i> , 2005 , 280, 28357-64	5.4	31

82	Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005 , 35, 720-6	2.8	17
81	Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005 , 35, 6-12	2.8	4
80	A Case of Extranodal NK/T Cell Lymphoma, Nasal Type Involving Anus. <i>The Korean Journal of Hematology</i> , 2005 , 40, 192		
79	Neoadjuvant Chemotherapy Followed by Radiotherapy in Epidermoid Carcinoma of Anus. <i>Tumori</i> , 2004 , 90, 299-302	1.7	1
78	Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. <i>Clinical Cancer Research</i> , 2004 , 10, 3708-16	12.9	644
77	Transforming growth factor-beta 1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells. <i>Molecular Biology of the Cell</i> , 2004 , 15, 420-34	3.5	74
76	Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2004 , 34, 400-4	2.8	19
75	Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. <i>Clinical Cancer Research</i> , 2004 , 10, 5271-81	12.9	128
74	Bcl-xL and E1B-19K proteins inhibit p53-induced irreversible growth arrest and senescence by preventing reactive oxygen species-dependent p38 activation. <i>Journal of Biological Chemistry</i> , 2004 , 279, 17765-71	5.4	49
73	Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. <i>Oncogene</i> , 2004 , 23, 1333-41	9.2	110
72	The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. <i>Oncogene</i> , 2004 , 23, 1724-36	9.2	136
71	Aberrant methylation of integrin alpha4 gene in human gastric cancer cells. <i>Oncogene</i> , 2004 , 23, 3474-80	9.2	45
70	Cdk2-dependent phosphorylation of the NF-Y transcription factor is essential for the expression of the cell cycle-regulatory genes and cell cycle G1/S and G2/M transitions. <i>Oncogene</i> , 2004 , 23, 4084-8	9.2	53
69	AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. <i>Oncogene</i> , 2004 , 23, 7095-103	9.2	79
68	Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. <i>Laboratory Investigation</i> , 2004 , 84, 479-84	5.9	180
67	Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 92, 927-35	4.9	54
66	Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004 , 130, 551-60	4.9	66
65	Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. <i>Cancer</i> , 2004 , 100, 1961-6	6.4	67

64	Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. <i>Cancer</i> , 2004 , 101, 2257-60	6.4	61
63	A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. <i>Cancer</i> , 2004 , 101, 2516-22	6.4	13
62	TGF-beta1 (transforming growth factor-beta1)-mediated adhesion of gastric carcinoma cells involves a decrease in Ras/ERKs (extracellular-signal-regulated kinases) cascade activity dependent on c-Src activity. <i>Biochemical Journal</i> , 2004 , 379, 141-50	3.8	25
61	The Role of Preoperative Chemotherapy in Patients with Inoperable Metastatic or Locally Advanced Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2004 , 4, 7	3.2	
60	Smad2 mediates Erk1/2 activation by TGF-beta1 in suspended, but not in adherent, gastric carcinoma cells. <i>International Journal of Oncology</i> , 2004 , 24, 1229-34	1	5
59	A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. <i>Oncology Reports</i> , 2004 , 12, 1059-64	3.5	32
58	Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma. <i>Acta Oncologica</i> , 2003 , 42, 779-83	3.2	66
57	A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells 2003 , 23, 1087		2
56	Analysis of spinal cord proteome in the rats with mechanical allodynia after the spinal nerve injury. <i>Biotechnology Letters</i> , 2003 , 25, 2071-8	3	12
55	Identification and characterization of a novel cancer/testis antigen gene CAGE-1. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2003 , 1625, 173-82		49
54	Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. <i>Cancer</i> , 2003 , 98, 2651-6	6.4	52
53	Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. <i>Oncogene</i> , 2003 , 22, 3943-51	9.2	97
52	Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 5745-51	8.3	45
51	Aberrant methylation of the specific CpG island portion regulates cyclooxygenase-2 gene expression in human gastric carcinomas. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 310, 844-51	3.4	25
50	Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003 , 39, 99-101	5.9	25
49	Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 307, 52-63	3.4	112
48	In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. <i>Peptides</i> , 2003 , 24, 945-53	3.8	85
47	Cdk2-dependent phosphorylation of the NF-Y transcription factor and its involvement in the p53-p21 signaling pathway. <i>Journal of Biological Chemistry</i> , 2003 , 278, 36966-72	5.4	59

46	Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. <i>Japanese Journal of Clinical Oncology</i> , 2003 , 33, 608-12	2.8	64
45	A Multi-Center, Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Cisplatin for Patients with Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2003 , 35, 30-4	5.2	4
44	Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. <i>Clinical Cancer Research</i> , 2003 , 9, 433-40	12.9	66
43	Chylothorax in Gorham's disease. <i>Journal of Korean Medical Science</i> , 2002 , 17, 826-9	4.7	23
42	Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. <i>Japanese Journal of Cancer Research</i> , 2002 , 93, 471-7		90
41	Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 75-80	4	39
40	p130 mediates TGF-beta-induced cell-cycle arrest in Rb mutant HT-3 cells. <i>Gynecologic Oncology</i> , 2002 , 86, 184-9	4.9	10
39	Docetaxel 75 mg/m ² is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. <i>Japanese Journal of Clinical Oncology</i> , 2002 , 32, 248-54	2.8	92
38	A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002 , 25, 238-43	2.7	39
37	Attenuation of transforming growth factor beta-induced growth inhibition in human hepatocellular carcinoma cell lines by cyclin D1 overexpression. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 292, 383-9	3.4	22
36	Identification and characterization of a novel cancer/testis antigen gene CAGE. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 292, 715-26	3.4	70
35	Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. <i>Cancer Letters</i> , 2002 , 184, 197-206	9.9	56
34	A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies. <i>Cancer</i> , 2001 , 91, 1549-56	6.4	12
33	Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells. <i>Oncogene</i> , 2001 , 20, 1254-65	9.2	49
32	Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. <i>Human Gene Therapy</i> , 2001 , 12, 671-84	4.8	108
31	CD99 regulates the transport of MHC class I molecules from the Golgi complex to the cell surface. <i>Journal of Immunology</i> , 2001 , 166, 787-94	5.3	46
30	Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2001 , 33, 469-73	5.2	2
29	Study of plasma TGF- β level as a useful tumor marker in gastric cancer and prostate cancer. <i>Immune Network</i> , 2001 , 1, 260	6.1	1

28	Transcriptional inactivation of the tissue inhibitor of metalloproteinase-3 gene by dna hypermethylation of the 5'-CpG island in human gastric cancer cell lines. <i>International Journal of Cancer</i> , 2000 , 86, 632-5	7.5	43
27	Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. <i>Cancer</i> , 2000 , 89, 2521-6	6.4	30
26	Methylation of specific CpG sites in the promoter region could significantly down-regulate p16INK4a expression in gastric adenocarcinoma. <i>International Journal of Cancer</i> , 2000 , 87, 236-240	7.5	52
25	Transforming growth factor-beta induces apoptosis in activated murine T cells through the activation of caspase 1-like protease. <i>Cellular Immunology</i> , 2000 , 204, 46-54	4.4	18
24	Loss of TGF-beta signaling contributes to autoimmune pancreatitis. <i>Journal of Clinical Investigation</i> , 2000 , 105, 1057-65	15.9	58
23	Transcriptional inactivation of the tissue inhibitor of metalloproteinase-3 gene by dna hypermethylation of the 5'-CpG island in human gastric cancer cell lines 2000 , 86, 632		1
22	Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 45, 901-5	4	18
21	Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells. <i>Oncogene</i> , 1999 , 18, 2213-9	9.2	33
20	Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer. <i>Oncogene</i> , 1999 , 18, 7280-6	9.2	119
19	Up-regulation of human telomerase catalytic subunit during gastric carcinogenesis 1999 , 86, 559-565		40
18	Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. <i>Cancer</i> , 1999 , 86, 1109-15	6.4	21
17	Rapidly developing T-cell posttransplantation lymphoproliferative disorder. <i>American Journal of Kidney Diseases</i> , 1999 , 34, e3.1-e3.5	7.4	4
16	Alteration of signal-transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients. <i>Pathobiology</i> , 1999 , 67, 123-8	3.6	16
15	Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II). <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 41, 109-16	3.5	6
14	Genetic integrity of transforming growth factor beta (TGF-beta) receptors in cervical carcinoma cell lines: loss of growth sensitivity but conserved transcriptional response to TGF-beta. <i>International Journal of Cancer</i> , 1998 , 77, 620-5	7.5	37
13	Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 250, 43-7	3.4	83
12	Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/beta2-microglobulin gene in patients with cancer. <i>Human Gene Therapy</i> , 1998 , 9, 2031-8	4.8	11
11	A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-beta type II receptor. <i>Journal of Biological Chemistry</i> , 1998 , 273, 110-7	5.4	91

10	A case of glomeruloid hemangioma associated with multicentric Castleman's disease. <i>American Journal of Dermatopathology</i> , 1998 , 20, 266-70	0.9	36
9	Myocardial Involvement of Carcinoid Heart Disease: A Case Report. <i>Journal of the Korean Society of Echocardiography</i> , 1998 , 6, 95		1
8	Alterations of p16INK4A and p15INK4B genes in gastric carcinomas. <i>Cancer</i> , 1997 , 80, 1889-96	6.4	57
7	Establishment and characterization of human gastric carcinoma cell lines. <i>International Journal of Cancer</i> , 1997 , 70, 443-9	7.5	100
6	Prognostic factors of patients with thymoma. <i>Korean Journal of Internal Medicine</i> , 1996 , 11, 40-9	2.5	7
5	The first documentation of Li-Fraumeni syndrome in Korea. <i>Journal of Korean Medical Science</i> , 1995 , 10, 205-10	4.7	7
4	Acceptance of Foreign Clinical Data. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 1994 , 2, 91		
3	A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. <i>Cancer</i> , 1993 , 71, 3813-8	6.4	323
2	A case of leukemia-associated arthritis--identification of leukemic cells in synovial fluid by light microscopy. <i>Journal of Korean Medical Science</i> , 1987 , 2, 255-8	4.7	4
1	A multi-center, late phase II clinical trial of Genexol \square (paclitaxel) and cisplatin for patients with advanced gastric cancer. <i>Oncology Reports</i> ,	3.5	3